PT-141 (Bremelanotide)
A cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R) acting centrally; FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women since 2019. Derived from the tanning peptide Melanotan II, PT-141 is widely discussed for male sexual function, though evidence for that application is limited to small studies outside the approved indication. Nausea is the most commonly reported adverse effect, and transient blood pressure elevation is documented in the prescribing information.
Side effects & risks
PT-141 / bremelanotide carries a documented human adverse-event profile because the approved pharmaceutical product (Vyleesi, Palatin Technologies) was evaluated in placebo-controlled Phase III trials. Those findings apply to the approved subcutaneous formulation at the approved dose. Research-chemical versions of bremelanotide sold online are not equivalent to Vyleesi and do not benefit from the controlled manufacturing, purity assurance, or dose-per-unit verification of the approved product.
In the Vyleesi Phase III programme — the RECONNECT trials (Kingsberg et al., 2019, Obstetrics and Gynecology, vol. 134; PMID 31599840) — the most commonly reported adverse events were nausea (40% of treatment subjects vs 1% placebo), flushing (20%), headache (11%), and transient hyperpigmentation. Nausea was often the primary reason for discontinuation in the trial; the RECONNECT trials assessed ondansetron co-administration, but the current Vyleesi prescribing information notes that pre-treatment ondansetron does not meaningfully reduce nausea and is not recommended. Transient increases in blood pressure were documented in a subset of trial participants; the Vyleesi prescribing information includes a contraindication for individuals with high cardiovascular disease risk for this reason.
A serious drug interaction risk exists with phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil). Bremelanotide combined with PDE5 inhibitors may cause additive hypotension, and the FDA label for Vyleesi notes that concomitant use is not recommended.
Skin hyperpigmentation — specifically, facial and breast hyperpigmentation — was documented in some participants in longer-term trial exposure periods. This was attributed to melanocortin receptor stimulation (the same mechanism responsible for PT-141's primary activity) acting on melanocytes. The prescribing information advises caution in individuals with darker skin tones.
For research-chemical bremelanotide (the version sold as PT-141 in peptide markets), the adverse-event profile from the Vyleesi trials provides the most relevant published human safety data, but the equivalence of purity, dose accuracy, and formulation between research-chemical preparations and the approved pharmaceutical cannot be assumed. Community-reported adverse events include nausea (consistent with trial data), facial flushing, headache, and elevated blood pressure.
PT-141 / bremelanotide is not a safe, risk-free compound. Individuals considering use should be aware of the cardiovascular contraindications identified in the Vyleesi prescribing information and the PDE5 inhibitor interaction.
Evidence summary
Latest studies
Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.
This analytical chemistry study developed a method to measure bremelanotide (PT-141) and identify its breakdown products under stress conditions. It concerns the compound's chemical stability and quality control, not its effects in people.
Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.
This is a drug-design and chemistry study. Researchers were trying to create new ring-shaped peptides (macrocycles) that can precisely target melanocortin receptors, a family of receptors (MC1R, MC3R, MC4R, MC5R) involved in things like appetite, inflammation, and pigmentation. They point to two approved macrocyclic peptide drugs, bremelanotide (PT-141) and setmelanotide, as proof that this class can succeed, and use that as motivation. They designed and made 14 new peptide variants and tested how each one acted on the four human receptor types. Two of the new molecules turned out to be strong, selective blockers of the MC4R receptor, and one selectively switched it on. The authors say these results help explain how a peptide's structure relates to its activity, which could guide future drug candidates for metabolic and inflammatory conditions. This is early laboratory work on brand-new experimental molecules; PT-141 is mentioned only as a reference example, and the study reports nothing new about PT-141 itself.
FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.
Amino acids, the building blocks of peptides and proteins, usually come in a "left-handed" (L) form in the body. Their mirror-image "right-handed" (D) versions are rare in nature but useful in drug design: enzymes that normally chop up peptides struggle to recognize the mirror-image building blocks, so drugs made with them last longer in the body, hold their shape better, and are less likely to provoke an immune reaction. This review traces how, since the mid-20th century, more than 20 FDA-approved drugs have included at least one D-amino acid. Examples range from natural products like gramicidin D to synthetic peptides such as desmopressin, leuprolide, bremelanotide, and etelcalcetide — the last being the first approved drug made entirely from D-amino acids. The article explains the mechanisms and medical uses of these drugs and the lab techniques that made them possible, including solid-phase peptide synthesis and mirror-image phage display. It is a historical and technical overview, not a study of how well any single drug performs.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Female HSDD (FDA-approved Vyleesi protocol) | SC injection (abdomen or thigh) | 1.75 mg | As needed, max 1× per 24 hours; max 8× per month | Discontinue if no benefit after 3 uses |
| Community-reported (research-chemical) | SC injection | 0.5–2 mg (lower starting dose for tolerance assessment) | As needed; 30–90 min before anticipated activity | Not applicable; on-demand use |
Frequently asked questions
- Is PT-141 the same as the FDA-approved drug Vyleesi?
- Bremelanotide is the active pharmaceutical ingredient in both Vyleesi (the FDA-approved drug) and in research-chemical products sold as PT-141. However, research-chemical PT-141 is not equivalent to Vyleesi: Vyleesi is a controlled pharmaceutical product manufactured to defined purity, dose, and sterility standards; research-chemical versions are not. The FDA approval applies specifically to the Vyleesi product for the approved female HSDD indication — it does not cover research-chemical PT-141 or off-label uses.
- What are the known risks of PT-141 / bremelanotide?
- In the Vyleesi Phase III trials, nausea occurred in approximately 40% of treatment participants, flushing in 20%, and headache in 11%. Transient blood pressure increases were documented and led to a cardiovascular contraindication in the prescribing information. Skin hyperpigmentation was reported with longer-term use. A serious drug interaction risk exists with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) due to additive hypotension risk. Research-chemical PT-141 carries additional uncertainty because purity and dose accuracy are not independently verified.
- Has PT-141 been studied in men?
- Yes, in Phase II controlled trials. Safarinejad and Hosseini (2008, Journal of Urology; PMID 18206919) evaluated bremelanotide in men with erectile dysfunction who had not responded to sildenafil and reported statistically significant improvements in erectile function scores compared to placebo. The development programme for a male indication did not proceed to Phase III; Palatin's regulatory focus shifted to the female HSDD indication. The male Phase II data is supportive but not sufficient for regulatory approval conclusions.
- How is PT-141 different from Viagra or tadalafil?
- PT-141 (bremelanotide) acts centrally, via melanocortin receptor agonism in hypothalamic sexual arousal circuits. PDE5 inhibitors (sildenafil, tadalafil) act peripherally, by inhibiting the enzyme that degrades cGMP in vascular smooth muscle, thereby facilitating blood flow. The proposed distinction is that PT-141 may act on desire or motivation circuitry, while PDE5 inhibitors facilitate vascular response. In practice, combining the two is associated with hypotension risk and is contraindicated by the Vyleesi label.
- Is PT-141 legal to buy or use?
- Vyleesi (the FDA-approved bremelanotide pharmaceutical) is a prescription-only drug in the United States. Research-chemical PT-141 is sold outside the pharmaceutical framework; its regulatory status varies by country. In some jurisdictions it requires a prescription; in others it is unscheduled. Community-sourced PT-141 is not subject to pharmaceutical manufacturing controls. Verify current regulatory status with a qualified legal or clinical professional.